FTC Subpoena Lawsuit Dismissed as Moot as Judge Ends WPATH Retaliation Case in Washington

A federal judge in Washington has closed the door on one of the most closely watched free-speech fights between the Trump administration and the medical establishment — not by deciding who was right, but by deciding that there was nothing left for a court to do. On Thursday, U.S. District Judge James Boasberg dismissed the lawsuit brought by the World Professional Association for Transgender Health, known as WPATH, against the Federal Trade Commission, ruling that the case had become moot because the FTC had revoked the subpoena at the heart of it.

The dismissal is a strange kind of ending, because the same judge had ruled only months earlier that WPATH was probably right on the law. In May, Boasberg blocked the FTC’s investigative demand after finding that it likely amounted to unlawful retaliation against the group for exercising its free-speech rights — its advocacy in favour of gender-affirming care. The FTC then changed course. In June it sued WPATH in federal court in Texas and withdrew the subpoena. That withdrawal, Boasberg wrote on Thursday, was enough to end the Washington case, whatever the court thought of how the agency had behaved while the subpoena was alive.

“This Court does not have jurisdiction to castigate federal agencies for past irresponsible or even unlawful conduct when its decree can have no concrete effect on the parties’ present rights and obligations,” Boasberg wrote. The sentence captures the legal logic of mootness in a single line: federal courts decide live disputes between parties, not arguments about conduct that has already stopped and cannot be undone by an order. WPATH and the FTC did not immediately respond to requests for comment on the ruling.

How the FTC subpoena fight began

WPATH is a nonprofit professional association that issues standards of care for the treatment of transgender patients, including young people with gender dysphoria. Its guidance is influential: hospitals, insurers and regulators around the world cite it when deciding which treatments to offer and which to cover. That influence is also what brought the group into the FTC’s sights. The commission enforces federal antitrust and consumer protection law, and it built its case on a consumer-protection theory — that WPATH’s public statements about the safety and benefits of gender-affirming treatments for minors were misleading.

WPATH sued the FTC in February 2026 in the U.S. District Court for the District of Columbia, in the case recorded as World Professional Association for Transgender Health v. Federal Trade Commission, No. 1:26-cv-00532. The group sought to block enforcement of the FTC’s civil investigative demand — the agency’s form of subpoena — arguing that the investigation was not a genuine consumer-protection inquiry but retaliation for protected speech, brought because the administration disapproved of the group’s recommendations. Its lawyers included Abbe Lowell of Lowell & Associates. The FTC was represented in the case by John Bailey of the Department of Justice.

Boasberg’s May ruling gave WPATH the strongest judicial finding it was ever going to get in Washington. Granting a preliminary injunction, he concluded that the group was likely to succeed on its First Amendment retaliation claim and that the investigative demand should be blocked. A preliminary finding of that kind is not a final judgment — it is a judge’s assessment, early in a case, of where the law is likely to land — but it put the FTC in the position of defending an investigation that a federal judge had publicly described as likely unlawful.

Why a revoked subpoena made the case moot

Rather than appeal the May ruling, the FTC stepped sideways. It withdrew the investigative demand, and in June it filed its own lawsuit against WPATH in federal court in Texas, joined by Republican-led states, alleging that the group made misleading statements about the safety of gender-affirming treatments — claims WPATH denies. From the agency’s point of view, it had simply chosen a different legal vehicle. From the court’s point of view in Washington, the choice emptied the original case of anything to decide. The subpoena WPATH had sued to block no longer existed, so an order blocking it would change nothing.

Mootness is one of the least dramatic doctrines in federal law and one of the most powerful. Courts apply it even when, as here, the party that benefits from the dismissal is the one that created the mootness by changing its own behaviour. The reason is constitutional: the judicial power extends to cases and controversies, and a dispute in which neither side can gain anything from a ruling is, in the law’s eyes, no longer either. Boasberg’s July decision had already signalled the shape of the ending. That month he denied WPATH’s request for a preliminary injunction that would have blocked the new Texas lawsuit from going forward, finding that the group could not show that defending the Texas case would cause it the kind of irreparable harm needed to stop it. The Thursday dismissal, issued without prejudice according to the case’s procedural posture, closes the Washington file while leaving the underlying fight very much alive elsewhere.

WPATH’s position throughout has been that the distinction between the two cases is artificial. In its filings, the group argued that the June lawsuit in Texas was the same campaign continued by other means: the investigation it called retaliatory did not end, it simply changed its legal form, moving from a compulsory demand for the group’s internal material to a public complaint seeking to establish that its published standards were deceptive. From that perspective, Thursday’s dismissal rewards a sequence — investigate, get enjoined, withdraw, refile elsewhere — that any agency could repeat against any organisation whose speech it dislikes, and each repetition would restart the legal clock in a new court. Boasberg’s order does not endorse that sequence; it holds only that the Constitution’s limits on what courts may decide leave the Washington court powerless to grade it after the fact. The difference between those two things — a court approving conduct, and a court declaring itself unable to judge conduct that has ended — is the whole substance of the ruling, and it is why both sides can plausibly claim something from it. The FTC can say the case against it was dismissed. WPATH can say the only judge to assess its retaliation claim while the subpoena lived found that claim likely to succeed. Neither statement is the final word on the law, and after Thursday, no judge in Washington is positioned to give one.

Two other professional groups took a different road to a similar destination. The Endocrine Society and the American Academy of Pediatrics, which had filed comparable challenges to FTC investigations into their own guidance on transgender health, previously settled their lawsuits, with the cases dismissed without prejudice. WPATH’s refusal to settle produced the May ruling in its favour — and then, once the agency withdrew its demand, a dismissal on grounds that say nothing about whether the FTC’s conduct was lawful.

The Texas lawsuit is where the fight continues

Nothing in Thursday’s ruling touches the case that now matters most. In the Northern District of Texas, the FTC and the states of Alaska, Iowa, Nebraska and Texas are pursuing their claim, filed on 17 June 2026, that WPATH facilitated misleading or unsubstantiated representations about the medical necessity, safety and effectiveness of gender-affirming treatments for minors. WPATH has moved to dismiss that case, arguing among other things that it does not sell anything to consumers, that its standards are professional and scientific speech, and that the FTC is stretching consumer-protection law to reach policy and opinion work by a nonprofit. Those arguments are allegations and defences, not findings; no court has decided them.

Related skirmishes continue on other fronts. The FTC has asked a federal court in Manhattan to enforce a subpoena against the Mount Sinai hospital group for records connected to the WPATH investigation, and has asked for that proceeding to be transferred to Texas. New York’s attorney general has required the hospital to observe the waiting period in the state’s shield law, which regulates responses to information requests about legally protected health care. No ruling on that enforcement request had been verified as of this week, and it is separate from both the dismissed Washington case and the Texas merits case.

Why the FTC subpoena ruling matters beyond one nonprofit

The case against WPATH sits inside a wider federal effort to restrict access to gender-affirming care, particularly for minors. Federal investigators have examined some of the country’s largest health systems over treatments including puberty blockers, hormone therapy and surgery. Several large hospital systems have agreed to stop providing such treatments and to set aside millions of dollars connected to patients, in settlements of federal probes, and last month two hospital operators agreed to pay $9.5 million to settle Justice Department claims that they improperly billed Medicaid for gender-affirming care provided to minors. The FTC’s role in that campaign is distinctive: it is the consumer-protection agency, and its theory treats medical guidance it disputes as a form of misleading commercial claim.

For nonprofits and professional associations of every political colour, the Washington dismissal carries a practical lesson about the limits of suing over an investigation. A group that wins an early ruling against a subpoena may still end up with no final judgment at all if the agency withdraws the demand and sues somewhere else, under a different theory, in a friendlier forum. The May finding that the FTC’s demand likely violated the First Amendment remains on the public record, and WPATH can cite it. But it is a preliminary assessment in a case that no longer exists, not a binding precedent that decides the Texas fight.

What remains undecided is nearly everything of substance: whether the FTC can lawfully treat a medical association’s treatment standards as misleading consumer claims, whether the investigation was in fact retaliation for speech, and what limits the First Amendment places on investigations aimed at organisations whose views an administration opposes. Those questions now travel to Texas, where the merits case will be argued on the FTC’s home ground of its own choosing. The Washington chapter is closed. The argument it started is not.

There is a final, quieter consequence worth noting for any reader trying to judge what happened here. Because the Washington case ended on mootness, there will be no damages, no injunction and no judicial order governing how the FTC conducts investigations of advocacy organisations in future. The May assessment stands as one judge’s preliminary view, persuasive to read but binding on no one. If the agency opens a similar inquiry tomorrow against a different group, that group would start again from the beginning — filing its own suit, seeking its own injunction, and hoping the demand is not withdrawn and refiled elsewhere before a final judgment can be reached. Whether that gap is a sensible feature of a system that reserves courts for live disputes, or a loophole that lets agencies investigate first and litigate never, is the question this case leaves behind for Congress, and it is likely to outlast the Texas litigation itself.

Sources

USN reviewed reporting from multiple outlets for this story. Read more from Reuters, Bloomberg Law and Bars Across.